Check for updates

OPEN ACCESS

EDITED BY Jiliang Zhou, Georgia Health Sciences University, United States

REVIEWED BY Huimei Wang, Fudan University, China Shilin Xia, Dalian Medical University, China

*CORRESPONDENCE Jiehua Li jiehuali_fs@163.com Xiaobing Pi pxbingice@163.com Ronghua Yang a_hwa991316@163.com

[†]These authors have contributed equally to this work and share first authorship

SPECIALTY SECTION

This article was submitted to Reconstructive and Plastic Surgery, a section of the journal Frontiers in Surgery

RECEIVED 10 July 2022 ACCEPTED 01 August 2022 PUBLISHED 17 August 2022

CITATION

Zhou S, Han Y, Yang R, Pi X and Li J (2022) TIMM13 as a prognostic biomarker and associated with immune infiltration in skin cutaneous melanoma (SKCM). Front. Surg. 9:990749. doi: 10.3389/fsurg.2022.990749

COPYRIGHT

© 2022 Zhou, Han, Yang, Pi and Li. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

TIMM13 as a prognostic biomarker and associated with immune infiltration in skin cutaneous melanoma (SKCM)

Sitong Zhou^{1†}, Yuanyuan Han^{2†}, Ronghua Yang^{3*}, Xiaobing Pi^{1*} and Jiehua Li^{1*}

¹Department of Dermatology, The First People's Hospital of Foshan, Foshan, China, ²Institute of Medical Biology, Chinese Academy of Medical Sciences and Peking Union Medical College, Yunnan Key Laboratory of Vaccine Research and Development on Severe Infectious Diseases, Kunming, China, ³Department of Burn and Plastic Surgery, Guangzhou First People's Hospital, South China University of Technology, Guangzhou, China

Objective: Providing protection against aggregation and guiding hydrophobic precursors through the mitochondria's intermembrane space, this protein functions as a chaperone-like protein. SLC25A12 is imported by TIMM8 as a result of its interaction with TIMM13. In spite of this, it is still unknown how TIMM13 interacts with skin cutaneous melanoma (SKCM) and tumor-infiltrating lymphocytes (TILs).

Methods: Aberrant expression of TIMM13 in SKCM and its clinical outcome was evaluated with the help of multiple databases, including the Xiantao tool (https://www.xiantao.love/), HPA, and UALCAN. TISIDB and Tumor Immune Estimation Resources (TIMER) databases were applied to explore the association between TIMM13 and tumor infiltration immune cells. OS nomogram was constructed, and model performance was examined. Finally, TIMM13 protein expression was validated by immunohistochemistry (IHC).

Results: TIMM13 expression was higher in SKCM samples than in peritumor samples. TIMM13 was strongly associated with sample type, subgroup, cancer stage, lymph node stage, and worse survival. Further, upregulation of TIMM13 was significantly associated with immunoregulators, and chemokines, as well as T cells, B cells, monocytes, neutrophils, macrophages, and T-cell regulators. An analysis of bioinformatic data uncovered that TIMM13 expression was strongly associated with PD1 (T-cell exhaustion marker). The nomogram showed good predictive performance based on calibration plot. TIMM13 was highly expressed in melanoma tissue samples than in normal samples.

Conclusion: In brief, TIMM13 may be a prognostic biomarker for SKCM. It might modulate the tumor immune microenvironment and lead to a poorer prognosis. In addition, it is necessary to study the targeted therapy of TIMM13.

KEYWORDS

cutaneous melanoma, translocase of inner mitochondrial membrane 13 (TIMM13), prognosis, biomarker, tumor immune microenvironment

Introduction

There are two main types of melanoma: cutaneous and uveal (1). Melanin-producing melanocytes in the skin are transformed into melanoma cells through malignant transformation (2). More than 75% of skin cancer deaths are caused by melanoma, even though it represents only 5% of all skin cancer cases (3). Cutaneous melanoma is considered the most aggressive type of skin cancer (4). There are approximately 232,100 (1.7%) new cases of cutaneous melanoma diagnosed worldwide (excluding nonmelanoma skin cancers), and the incidence of cutaneous melanoma is around 55,500 deaths per year (0.7% of all cancer deaths) (5). Before the FDA's approved targeted and immunotherapy strategies in 2011 and 2014, metastatic melanoma was thought to be incurable and not treatable (6). These strategies are effective in treating some cases of melanoma, but not all, due to toxicity, intrinsic resistance to drugs, and other unidentified causes (7). It is necessary to perform surgery, radiotherapy, chemotherapy, and conduct clinical trials to cure resistant melanoma cells (8). With SKCM, the discovery of new immunotherapy targets and the detection of immune-related biomarkers are urgent tasks.

The TIMM13 gene encodes a chaperone protein that is part of the evolutionarily conserved TIMM (translocase of inner mitochondrial membrane) family that assists in the transport of proteins into mitochondria from the cytosol (9). The TIMM13 gene prevents hydrophobic precursors from aggregating and guides the proteins passing the mitochondrial intermembrane. SLC25A12/ARALAR1 and SLC25A13/ARALAR2 are imported by the TIMM8-TIMM13 complex (10). Timm13 is associated with Mohr-Tranebjaerg Syndrome and Visual Cortex Disease (11). It is related to the Peroxisomal lipid metabolism pathway (12). Studies have shown that TIMM13 was differently expressed in metastatic susceptibility (13), hepatocellular carcinoma (14), breast cancer (15) et al. These research proposed that TIMM13 may impact cancer profoundly, and it may be considered a new target for dealing with various malignant tumors. However, the possible mechanisms of TIMM13 in tumorigenesis and immune involvement in SKCM is still unclear.

In the study, the expression of TIMM13 and its connection with the clinical outcomes of SKCM were explored by various databases, including the Xiantao tool, HPA, and UALCAN databases. In addition, the Xiantao tool and TIMER database was conducted to explore the connection of TIMM13 with the infiltration of immune cells. The TISIDB database was used to study the relationship between TIMM13 and immunomodulators, immunostimulators, and chemokines. This research revealed the important function of TIMM13 in SKCM, and then the possible relationship and possibility of TIMM13 regulating tumor invasion of immune cells.

Materials and methods

Interaction analysis of gene expression profiling

The Xiantao tool online database (https://www.xiantao.love/) (16) is an integrated platform using R software (3.6.3) for obtaining analytical data from TCGA (https://portal.gdc.cancer.gov/) (17) and The Genotype–Tissue Expression (GTEx) (https://gtexportal.org/home/) (18). R packages used in the Xiantao tool were set as default. In the study, we evaluated TIMM13 expression in SKCM and normal tissues using the Xiantao data source.

UALCAN database analysis

The UALCAN website (http://ualcan.path.uab.edu/) contains massive bioinformatics and clinical data on 31 TCGA malignant tumors (19). It can be used to make a gene expression comparison between SKCM and normal samples, at different tumor stages, different subtypes, and other clinicopathological characteristics. In the research, the expression level of TIMM13 will be determined by the main clinicopathological characteristics, such as tissue category (healthy or tumor), SKCM stage (stages 1, 2, 3, 4), lymph node stage (N01 stage, 2, 3), cancer subgroup, etc. The clinicopathological features (tumor degree, stage) and TIMM13 expression distribution of patients were collected by the UALCAN database and Xiantao tool for correlation analysis.

Survival analysis for SKCM

Based on the median of the expression of TIMM13, patients were divided into a high TIMM13 expression group and a low TIMM13 expression group. The prognostic significance of TIMM13 in SKCM, including overall survival (OS), and progression-free interval (PFI), were explored using the Xiantao tool between the high TIMM13 expression group and low TIMM13 expression group. The hazard ratio (HR) with 95% confidence intervals and log-rank p-value was estimated. P < 0.05 was regarded as statistical significance.

Tumor immune infiltration analysis

ssSGSEA method was applied to explore the potential connection between TIMM13 mRNA expression and immune infiltration level in SKCM by TIMER 2.0 (http://timer.cistrome.org/) (20). In addition, TILs gene markers and TILs gene expression were analyzed by the Xiantao

tool. Then we drew the expression dispersion maps between a pair of custom genes for SKCM and the statistical significance of the correlation was estimated by Spearman's method. log2 RSEM was applied to exhibit the levels of gene expression.

TISIDB database analysis

TISIDB (http://cis.hku.hk/TISIDB/) (21) is an online platform for studying tumor-immune system interaction, which combines various heterogeneous data sources. This database can assist us to know the interaction between tumors and immune cells, predict the responses of the body to immunotherapy, and find out novel immunotherapy targets. It will be a precious basis for tumor immunology studies and treatment. In this study, we used TISIDB to study the relationship between TIMM13 and 28 TILs, 45 immunopotentiators, 24 immunosuppressants, 41 chemokines, and 18 receptors in SKCM.

Building and validation of a nomogram

A nomogram is a statistical model of prognosis presented as a simple graph. In the nomogram, each sample is assigned a point for each of its variables and the resulting total score predicts 1-, 3-, and 5-year survival rates. We used independent prognostic factors to build a nomogram using the "rms" package. A calibration plot (by a bootstrap method with 500 resamples) was used to validate the nomogram and concordance index (C-index).

Immunohistochemistry (IHC) staining

Paraffin-embedded tissues were sectioned at 4 μ m for IHC analysis. Antigens were retrieved by incubating the samples in citrate buffer (pH 6.0) for 15 min at 100 °C in a microwave oven and naturally cooled to room temperature. After blocking with a mixture of methanol and 0.75% hydrogen peroxide, sections were incubated overnight with appropriate dilatation of primary antibodies (TIMM13, Invitrogen, 1:150) followed by incubation with a secondary antibody conjugated with HRP (goat anti-rabbit, 1:500, Cell Signalling Technology). The sections were washed three times with PBS and incubated with AEC (ZSGB-BIO).

Statistical analysis

Statistical analyses were performed with the Student t test, the Mann-Whitney U test, or analysis of variance, as

appropriate. For nonparametric (non-normally distributed) data, Mann–Whitney U test was used for statistical analysis. The survival curve was drawn by KM plot by log-rank test. We calculated Spearman's correlation coefficient to explore the relationship between TIMM13 expression and immune infiltration levels, immunomodulators, and chemokines. Statistically significant was regarded as p < 0.05.

Results

High expression of TIMM13 in SKCM tissue

The differential expression of TIMM13 in tumor and normal tissues were studied by RNA-seq data of different types of cancer from TCGA. The conclusion was shown in **Figure 1A**. According to Xiantao tool, we found that the expression of TIMM13 upregulated in almost all cancer tissues such as ACC, BLCA and SKCM, but downregulated in KIRC, LAML and PCPG.

To validate these results in SKCM, cancer samples from the TCGA database and normal samples from GTEx database were tested by xiantao tool. As shown in **Figure 1B**, it was found that TIMM13 mRNA expression was significantly higher in SKCM samples (469 cases) than that in normal samples (813 cases) (p < 0.05) from GETx. Based on the HPA website, immunohistochemistry confirmed the TIMM13 protein expression pattern (**Figure 1C**). It is worth noting that the increased expression of TIMM13 mRNA was negatively correlated with PD1 (**Figure 1D**), where the AUC of TIMM13 in SKCM is 0.757 (95% CI is 0.727 to 0.786) (**Figure 1E**). It is suggested that TIMM13 was significantly elevated in SKCM tissues, which may be a potential biomarker for the diagnosis of SKCM.

Relationship between TIMM13 expression and patient clinical pathology in SKCM

Using the UALCAN and the Xiantao tool, we investigated the relationship between TIMM13 expression and several clinicopathological features, such as tumor type, stage, lymph node stage, and TP53 mutation shown in **Figure 2A**, the expression of TIMM13 in SKCM metastatic cancer tissues was significantly higher than that in primary cancer tissues and normal cancer tissues (p = 0.0018). There was no significant difference between different cancer stages (**Figure 2B**), different lymph nodes (**Figure 2C**) and TP53 mutation (**Figure 2D**). Secondly, in order to further understand the function and possible mechanism of



TIMM13 expression levels. (A) Increased or decreased TIMM13 in different tumor types from The Cancer Genome Atlas (TCGA) database were determined by Xiantao tool (*p < 0.05, **p < 0.01, **p < 0.001). (B) Increased TIMM13 in SKCM tissues compared with normal tissues. (C) TIMM13 immunohistochemical staining levels in SKCM tissues (up) and normal tissues (down) by using HPA database. (D) The correlation analysis between TIMM13 and PD1 mRNA level. (E) The receiver-operating characteristic (ROC) curve analysis of TIMM13 in SKCM patients.



TIMM13 in tumorigenesis, we used univariate and multivariate Cox regression analysis to observe the correlation between TIMM13 expression and clinicopathological features of SKCM. The up-regulation of TIMM13 expression was related to a poorer OS (HR = 2. 199, p < 0.001) (Table 1), DSS (Table 2) (HR = 2. 442, p <0.001) and PFI (Table 3) (HR = 1. 439, p = 0. 027) in SKCM patients. The increase of TIMM13 mRNA expression was related to a poorer OS in T4 stage (HR = 4. 500, p = 0.010), N2 stage (HR = 3. 617, p = 0. 048), N3 stage (HR = 11. 432, p < 0.001), melanoma ulceration (HR = 1. 650, p = 0.030), and Melanoma Clark V level (HR = 4. 519, p = 0.043) SKCM patients. Furthermore, we found that DSS and PFI in T4 stage (DSS HR = 3.415, p = 0.039), N1 stage (DSS HR = 4.736, p = 0.044), N2 stage (DSS HR = 5.521, p =0.027), N3 stage (DSS HR = 17.411, p < 0.001; PFI HR = 5.829, *p* < 0.001), Melanoma Clark V level (DSS HR = 5.338, p = 0.028; PFI HR = 3.211, p = 0.021) were associated with TIMM13 expression. It was a hint that the prognostic effect of TIMM13 in SKCM might be influenced by their clinical characteristics.

Increased TIMM13 mRNA expression associated with poor overall survival in SKCM patients

It was suggested that the expression level of TIMM13 mRNA in SKCM patients is higher than that in the normal control group. Therefore, whether the expression of TIMM13 was related to tumor prognosis needs further study. In this study, the expression of TIMM13 and its relationship with prognosis were detected by the Kaplan–Meier survival curve to determine whether TIMM13 can be used as a biomarker for prognosis of SKCM. It was worth noting that the high expression of TIMM13 was associated with a poorer outcome of SKCM. High expression of TIMM13 was associated with poorer OS, and PFI (Figures 3A,B).

Hazard ratio p value Hazard ratio p -value Gender 456 Fernale 172 Reference Male 284 L172 (0.679-1.563) 0.281 Pathologic stage 410 1.586 (1.054-2.385) 0.027 0.279 (0.111-0.703) 0.007 Stage II 170 Reference 353 0.027 0.279 (0.111-0.703) 0.007 Stage II 170 1.983 (1.342-3.927) -0.001 0.166 (0.604.0.699) 0.014 Stage II 170 1.983 (1.342-3.927) -0.001 0.166 (0.604.0.699) 0.017 Stage II 170 1.983 (1.342-3.927) -0.001 0.166 (0.604.0.699) 0.014 Stage II 172 1.491 (0.614-2.169) 0.197 1.539 (0.620-3.768) 0.011 Yage 361 224 Reference 292 (0.664-8.871) 0.058 Yadge 1.127 (2.07-6.653) <0.01 1.328 (0.085-12.27) 0.016 Na dage 224 Reference 292 (0.664-8.871) 0.058	Characteristics	Total (N)	Univariate analysis		Multivariate analysis	
Gender 456 Fenale 172 Reference Male 284 1.172 (0.879-1.563) 0.281 Pathologic stage 40 Stage I 77 Reference Stage II 140 1.586 (1.054-2.385) 0.027 0.279 (0.111-0.703) 0.007 Stage II 140 1.586 (1.054-2.385) 0.021 0.221 (0.047-1.045) 0.037 Stage IV 23 3.517 (1.781-6.944) <0.001 0.221 (0.047-1.045) 0.037 T tage 361 0.015 2.94 (0.964-8.871) 0.058 T3 90 2.077 (1.188-3.788) 0.015 2.94 (0.964-8.871) 0.058 T4 153 3.711 (2.070-6.653) <0.001 1.439-1.11 0.01 Nage 402 0.052 1.439-1.039 0.051 N3 56 2.731 (1.789-4.215) <0.001 1.1432 (3.201-0.822) <0.001 N4			Hazard ratio (95% CI)	<i>p</i> -value	Hazard ratio (95% CI)	<i>p</i> -value
Fende 172 Reference Male 284 Marcon Stage I 77 Reference Stage II 164 1586 (1.054.2.058) 0.027 0.279 (110.0.703) 0.007 Stage II 164 1586 (1.054.2.058) 0.007 0.279 (0.110.0.703) 0.007 Stage II 164 1586 (1.054.2.058) 0.007 0.221 (0.047.1.0.43) 0.001 Stage II 172 3.03 0.001 0.221 (0.047.1.0.43) 0.036 Stage II 173 1.495 (0.011.2.756) 0.197 1.529 (0.020.3.768) 0.036 Tage 3.01 2.021 (0.047.1.043.1.256) 0.197 1.529 (0.020.3.768) 0.036 Tage 3.01 2.021 (0.047.2.169) 0.031 2.024 (0.045.4.11) 0.031 Stage II 1.02 0.077 (1.152.3.03 0.001 1.323 (0.01.4.51.4.11) 0.001 Na 2.02 1.027 (1.014.2.101) 0.061 3.047 (0.012.1.2.391) 0.061 Na 3.02 2.021 (1.070.3.410) 0.061	Gender	456				
Mak1481.172 (0.879-1.563)0.281Patholog range410Shage I70ReferenceShage II1701.586 (1.542.385)0.0270.279 (0.111-0.703)0.007Shage III1701.586 (1.542.385)0.0210.279 (0.011-0.703)0.007Shage III1701.586 (1.542.385)0.0010.166 (0.040-0.695)0.014Shage III1701.587 (0.057-0.057)0.0050.057Shage III1711.987 (0.057-0.057)0.0560.015Tatage1711.987 (0.054.538)0.0015.2924 (0.064.587)0.056Tatage1630.207 (1.158.378)0.0015.2924 (0.064.587)0.056Tatage1630.207 (1.158.378)0.0015.2924 (0.064.587)0.056Natage1630.207 (1.158.378)0.0014.500 (1.137.141)0.010Natage1630.207 (1.158.378)0.0065.017 (1.01.21.230)0.048Natage1630.2131 (1.07.241)0.0665.017 (1.01.21.230)0.001Natage164Reference4.000 (0.051.212)0.0112.123 (3.01.40.22)0.001Natage164S.201 (1.05.212)0.0515.017 (1.01.21.230)0.001Natage164Reference4.000 (0.051.225)0.0514.000 (0.051.225)0.011Natage164S.201 (1.05.201)0.0115.010.05.292)0.011Natage164Reference4.000 (0.051.255)0.0112.014 (0.0	Female	172	Reference			
Pablogic targe410Sage I77ReferaceSage II1401.86 (1.054.205)0.0270.279 (0.111.4703)0.007Sage IV233.57 (1.731.494)<0.01	Male	284	1.172 (0.879-1.563)	0.281		
Singe I 77 Reference Singe III 140 1.580 (1.054.2.35) 0.027 0.279 (0.111-0.703) 0.007 Singe III 140 1.580 (1.054.2.35) 0.001 0.620 (1.01-0.703) 0.017 Singe III 140 1.591 (1.42-32) 0.001 0.221 (0.07-1.05) 0.015 T stage 3.61	Pathologic stage	410				
Stage II 140 1.586 (1.054-2.385) 0.027 0.279 (0.111-0.703) 0.007 Stage II 170 1.683 (1.344-2.927) -0.001 0.166 (0.040-0.95) 0.014 Stage IV 23 3.577 (1.781-6.940) -0.001 0.016 (0.040-0.95) 0.017 Stage IV 23 3.577 (1.781-6.940) 0.001 0.221 (0.047-1.045) 0.057 Tage 64	Stage I	77	Reference			
Stage II 170 1,983 (1,342-297) <0.001 0.166 (0.040-0.595) 0.014 Stage IV 23 3,517 (1,781-6,44) <0.001 0.221 (0.047-1.045) 0.057 T stage 361 0.057 T f 41 Reference 1,599 (0.620-3,768) 0.058 T 4 0.30 2,097 (1,158-3,788) 0.015 2,294 (0.964-8,871) 0.058 T 4 0.30 2,097 (1,158-3,788) 0.015 2,294 (0.964-8,871) 0.058 T 4 0.30 2,017 (1,070-6,633) 0.010 1,435 (0.135-14,111) 0.016 N 4 40 0.224 Reference 3.489 (0.968-12,327) 0.052 N 5 2,731 (1.09-4,215) 0.066 3.617 (1.012-12,301) 0.010 3.230 (0.0168-12,327) 0.010 M 3 are 0.30 Reference 3.300 (0.121,123,123,123,123,123,123,123,123,123,	Stage II	140	1.586 (1.054-2.385)	0.027	0.279 (0.111-0.703)	0.007
İsige IV 23 3.517 (1.781-634) 0.001 0.221 (0.047-1.045) 0.057 T stage 61	Stage III	170	1.983 (1.344-2.927)	<0.001	0.166 (0.040-0.695)	0.014
T stage 361 T I 41 Reference T Q 1.495 (0.812-526) 0.915 1.529 (0.50.37.68) 0.035 T A 0.33 0.315 0.326 (0.50.37.68) 0.035 T A 0.33 0.311 (2.07.6.6.33) 0.001 4.500 (1.43.51.4111) 0.010 N stage 402 Reference 700 1.497 (0.14.2.210) 0.066 3.489 (0.988-12.327) 0.003 N A 2.34 Reference 3.430 (0.72.2.419) 0.066 3.617 (1.01.2.12.30) 0.004 N A 5.6 2.731 (1.769.4.215) -0.001 1.1432 (3.201.40.822) -0.001 M atge 4.39 0.898.12.327) 0.006 3.617 (1.01.2.12.30) 0.004 M atge 4.39 0.897.2.419 0.006 3.617 (1.01.2.12.30) 0.001 M atge 4.39 0.897.2.419 0.001 1.1432 (3.201.40.822) -0.001 M atge 4.39 0.897.2.419 0.004	Stage IV	23	3.517 (1.781-6.944)	<0.001	0.221 (0.047-1.045)	0.057
Tl 41 Reference T2 77 1.495 (0.811-2.756) 0.197 1.529 (0.620-3.768) 0.056 T3 90 2.097 (1.158-3.798) 0.001 2.924 (0.944-8.871) 0.056 T4 0.50 0.001 2.924 (0.944-8.871) 0.001 N stage 0.001 4.500 (1.435-14.110) 0.001 N stage 0.021 Reference 0.001 3.489 (0.988-12.327) 0.052 N1 73 1.497 (1.014-2.210) 0.043 3.489 (0.988-12.327) 0.052 N2 4.9 1.514 (0.972-2.419) 0.006 3.617 (1.012-12.930) 0.014 M stage 430 1.534 (0.972-2.419) 0.006 3.617 (1.012-12.930) 0.014 M stage 430 1.594 (0.972-2.419) 0.001 1.1432 (3.201-0.822) 0.014 M stage 430 Reference 1.591 (0.502-1.910) 0.01 1.432 (3.201-0.821) 0.01 Turkis staite 192 Reference 1.291 (0.752-131) 0.308 0.01 1.591 (1.052-5.921) 0.01 Malonea stark level 157 1.649 (0.591-125)	T stage	361				
T2 77 1.495 (0.811-2756) 0.197 1.529 (0.620.3768) 0.035 T3 90 2.097 (1.158.3798) 0.015 2.924 (0.964.8.871) 0.088 T4 153 3.71 (207-653) <0.001	T1	41	Reference			
T3902.097 (1.158-3798)0.0152.924 (0.964-8.87)0.015T41533.711 (2.070-6.653) $<$ 0.001 4.500 (1.453-14.11)0.010N stage402 $<$	Т2	77	1.495 (0.811-2.756)	0.197	1.529 (0.620-3.768)	0.356
T4 153 3.711 (2.070-6.653) -0.001 4.500 (1.435-14.11) 0.010 N stage 420 Reference N N 124 Reference N1 73 1.497 (1.012-2.10) 0.043 3.489 (0.988-12.37) 0.021 N2 49 1.530 (0.072-2.419) 0.006 3.617 (1.012-12.900) 0.048 N3 56 2.731 (1.769-4.215) -0.001 1.1432 (3.201-40.822) -0.001 M stage 430 -	Т3	90	2.097 (1.158-3.798)	0.015	2.924 (0.964-8.871)	0.058
N sige: 40 N0 24 Reference N1 73 1.497 (1.014-2.01) 0.043 3.489 (0.988-12.32) 0.052 N2 49 1.534 (0.972-2.419) 0.060 3.617 (1.012-12.93) 0.044 N3 56 2.537 (1.799-4.215) 0.060 3.617 (1.012-12.93) 0.040 M stage: 43 2.373 (1.799-4.215) 0.060 3.617 (1.012-12.93) 0.040 M stage: 43 1.897 (1.029-3.496) 0.404	T4	153	3.711 (2.070-6.653)	<0.001	4.500 (1.435-14.111)	0.010
N0 224 Reference N1 73 1.497 (1.014-2.210) 0.043 3.489 (0.988-12.327) 0.052 N2 49 1.534 (0.972-2.419) 0.066 3.617 (1.012-12.930) 0.048 N3 56 2.731 (1.769-4.215) <0.001	N stage	402				
N1 73 1.497 (1.014-2.210) 0.043 3.489 (0.988-12.327) 0.051 N2 49 1.534 (0.972-2.419) 0.066 3.617 (1.012-12.930) 0.043 N3 56 2.731 (1.769-4.215) <0.001	N0	224	Reference			
N2 49 1.534 (0.972-2.419) 0.066 3.617 (1.012-12.93) 0.048 N3 56 2.731 (1.769-4.215) <0.001	N1	73	1.497 (1.014-2.210)	0.043	3.489 (0.988-12.327)	0.052
N3 56 2.731 (1.769-4.215) <0.01 1.1.432 (3.201-40.822) <0.001 M stage 430	N2	49	1.534 (0.972-2.419)	0.066	3.617 (1.012-12.930)	0.048
M stage 430 M0 460 Reference M1 24 1.837 (1.029-3.496) 0.040 Tumor tissue site 302	N3	56	2.731 (1.769-4.215) <0.001		11.432 (3.201-40.822)	< 0.001
M0406ReferenceM1241.897 (1.029-3.496)0.400Tumor tissue site302522Externities100ReferenceTrunk1660.940 (0.693-1.275)0.691Head and Neck361.269 (0.755-2.131)0.368M2 lanoma ulceration313743740No146Reference746Yes1672.085 (1.495-2.907) $<$ 0.0011.650 (1.050-2.592)0.030M2 lanoma clark level315741 2.340 (0.669-0.939)0.218If and II19Reference741 2.340 (0.606-9.039)0.218If And II19Reference741 2.340 (0.606-9.039)0.218If And II1672.945 (1.286-6.747)0.0112.704 (0.701-10.435)0.014V535.449 (2.285-13.177) $<$ 0.0014.519 (1.06-19.532)0.001V535.449 (2.182-13.177) $<$ 0.0014.519 (1.046-19.532)0.014Age-456Feference741 $<$ 0.0112.58 (0.847-1.870)0.206Solo260Reference741 $<$ 0.0011.258 (0.847-1.870)0.206M133546Feference741 $<$ 0.0011.258 (0.847-1.870)0.026Solo2101.219 (1.292)4.0011.258 (0.847-1.870)0.266Solo2101.219 (2.192)3.0012.199 (1.498-3.228) $<$ 0.001Solo2101.211 (1.372-241) $<$ 0.0012.199 (1.498-3.2	M stage	430				
M1241.897 (1.029-3.496)0.040 $Turor tissue site392Extendities190ReferenceTrunk1660.940 (0.693-1.275)0.691Head and Neck361.269 (0.755-2.131)0.368McIaroma ulceration313$	M0	406	Reference			
Turor tissue site92Extremities190ReferenceTrunk1660.940 (0.693-1.275)0.691Head and Neck361.269 (0.755-2.131)0.368Melanoma ulceration313	M1	24	1.897 (1.029-3.496)	0.040		
Extremities 190 Reference Trunk 166 0.940 (0.693-1.275) 0.691 Head and Neck 36 1.269 (0.755-2.131) 0.368 Melanoma ulceration 313	Tumor tissue site	392				
Trunk 166 0.940 (0.693-1.275) 0.691 Head and Neck 36 1.269 (0.755-2.131) 0.368 Melanoma ulceration 313	Extremities	190	Reference			
Head and Neck 36 1.269 (0.755-2.131) 0.368 Melanoma ulceration 313 No 146 Reference Yes 167 2.085 (1.495-2.907) <0.001	Trunk	166	0.940 (0.693-1.275) 0.691			
Melanoma ulceration 513 No 146 Reference Yes 167 2.085 (1.495-2.907) <0.001	Head and Neck	36	1.269 (0.755-2.131)	0.368		
No 146 Reference Yes 167 2.085 (1.495-2.907) <0.001	Melanoma ulceration	313				
Yes 167 2.085 (1.495-2.907) <0.001 1.650 (1.050-2.592) 0.030 Melanoma clark level 315 .	No	146	Reference			
Melanoma clark level 315 I and II 19 Reference III 76 1.679 (0.704.4.002) 0.243 2.340 (0.606-9.039) 0.218 IV 167 2.945 (1.286-6.747) 0.011 2.704 (0.701-10.435) 0.149 V 53 5.449 (2.253-13.177) <0.001	Yes	167	2.085 (1.495-2.907)	<0.001	1.650 (1.050-2.592)	0.030
I and II 19 Reference III 76 1.679 (0.704.4.002) 0.243 2.340 (0.606-9.039) 0.218 IV 167 2.945 (1.286-6.747) 0.011 2.704 (0.701-10.435) 0.149 V 53 5.449 (2.253-13.177) <0.001	Melanoma clark level	315				
III 76 1.679 (0.704-4.002) 0.243 2.340 (0.606-9.039) 0.218 IV 167 2.945 (1.286-6.747) 0.011 2.704 (0.701-1.0435) 0.149 V 53 5.449 (2.253-13.177) <0.001	I and II	19	Reference			
IV 167 2.945 (1.286-6.747) 0.011 2.704 (0.701-10.435) 0.149 V 53 5.449 (2.253-13.177) <0.001	III	76	1.679 (0.704-4.002)	0.243	2.340 (0.606-9.039)	0.218
V 53 5.449 (2.253-13.177) <0.001 4.519 (1.046-19.532) 0.043 Age 456 0.043 ≤60 246 Reference 0.256 >60 210 1.656 (1.251-2.192) <0.001 1.258 (0.847-1.870) 0.256 TIMM13 456 <t< td=""><td>IV</td><td>167</td><td>2.945 (1.286-6.747)</td><td>0.011</td><td>2.704 (0.701-10.435)</td><td>0.149</td></t<>	IV	167	2.945 (1.286-6.747)	0.011	2.704 (0.701-10.435)	0.149
Age 456 ≤60 246 Reference >60 210 1.656 (1.251-2.192) <0.001	V	53	5.449 (2.253-13.177)	<0.001	4.519 (1.046-19.532)	0.043
≤60 246 Reference >60 210 1.656 (1.251-2.192) <0.001	Age	456				
>60 210 1.656 (1.251-2.192) <0.001 1.258 (0.847-1.870) 0.256 TIMM13 456	<u>≤</u> 60	246	Reference			
TIMM13 456 Low 230 Reference High 226 1.711 (1.307-2.241) <0.001 2.199 (1.498-3.228) <0.001	>60	210	1.656 (1.251-2.192)	<0.001	1.258 (0.847-1.870)	0.256
Low 230 Reference High 226 1.711 (1.307-2.241) <0.001	TIMM13	456				
High 226 1.711 (1.307-2.241) < 0.001 2.199 (1.498-3.228) < 0.001	Low	230	Reference			
	High	226	1.711 (1.307-2.241)	<0.001	2.199 (1.498-3.228)	< 0.001

TABLE 1 Univariate and multivariate Cox regression analysis of OS.

Bold values represent significantly different.

Correlation between immune infiltration and TIMM13 expression in SKCM

Immune infiltration plays an important role in tumor progression. We observed whether the expression of TIMM13

affected the number of tumors infiltrating lymphocytes (TILs) in SKCM by using the Xiantao tool. As a result, the expression of TIMM13 was negatively correlated with StromalScore, ImmuneScore, and ESTIMATEScore of SKCM (rho = -0.307, p < 0.001; rho = -0.398, p < 0.001; rho = -0.393, p < 0.001,

Characteristics	Total (N)	Univariate analysis		Multivariate analysis	
		Hazard ratio (95% CI)	<i>p</i> -value	Hazard ratio (95% CI)	<i>p</i> -value
Gender	450				
Female	172	Reference			
Male	278	1.161 (0.855-1.575)	0.340		
Pathologic stage	405				
Stage I	76	Reference			
Stage II	139	1.496 (0.977-2.291)	0.064	0.299 (0.115-0.773)	0.013
Stage III	167	1.777 (1.181-2.672)	0.006	0.125 (0.024-0.660)	0.014
Stage IV	23	3.800 (1.914-7.547)	<0.001	0.178 (0.031-1.019)	0.052
T stage	356				
T1	41	Reference			
T2	76	1.435 (0.775-2.657)	0.250	1.390 (0.557-3.470)	0.481
Т3	88	1.934 (1.060-3.529)	0.032	2.562 (0.835-7.863)	0.100
T4	151	3.110 (1.715-5.637)	<0.001	3.415 (1.066-10.944)	0.039
N stage	396				
N0	221	Reference			
N1	71	1.279 (0.827-1.976)	0.269	4.736 (1.041-21.537)	0.044
N2	49	1.473 (0.905-2.398)	0.120	5.521 (1.212-25.162)	0.027
N3	55	2.920 (1.867-4.565) <0.001		17.411 (3.852-78.698)	< 0.001
M stage	424				
M0	400	Reference			
M1	24	2.200 (1.190-4.069)	0.012		
Tumor tissue site	386				
Extremities	188	Reference			
Trunk	164	0.920 (0.664-1.274)	0.615		
Head and neck	34	1.271 (0.720-2.244)	0.407		
Melanoma ulceration	309				
No	145	Reference			
Yes	164	1.948 (1.372-2.767)	<0.001	1.593 (0.993-2.555)	0.053
Melanoma clark level	310				
I and II	19	Reference			
III	76	1.898 (0.739-4.877)	0.183	2.270 (0.580-8.891)	0.239
IV	163	3.235 (1.307-8.005)	0.011	2.814 (0.723-10.951)	0.136
V	52	5.779 (2.206-15.141)	<0.001	5.338 (1.204-23.670)	0.028
Age	450				
≤60	244	Reference			
>60	206	1.699 (1.258-2.294)	<0.001	1.246 (0.819-1.895)	0.304
TIMM13	450				
Low	227	Reference			
High	223	1.798 (1.348-2.399)	<0.001	2.442 (1.621-3.677)	<0.001

TABLE 2 Univariate and multivariate Cox regression analysis of DSS.

Bold values represent significantly different.

respectively) (**Figure 4A**). Our results also revealed a significant correlation between TIMM13 and TILs abundance (**Figure 4B**). The high expression of TIMM13 was negatively correlated with the infiltration of Th1 cells (rho = -0.416) (**Figure 4C**) and T

lymphocytes (Rho = -0.415) (Figure 4D), aDC cells (rho = -0.338) (Figure 4E), TFH cells (rho = -0.366) (Figure 4F), B lymphocytes (Rho = -0.359) (Figure 4G) and T helper T cells (rho = -0.354) (Figure 4H). All the *p*-values above were <0.001.

Harard ratio p-value Hazard ratio p-value Gender 47 Finale 172 Reference Mak 285 1.037 (0.821-1.309) 0.763 Patholgic stage 411 Stage II 10 1.581 (0.984-1.549) 0.065 0.411 (0.194-0.877) 0.021 Stage II 17 Reference 0.337 (0.112-1.179) 0.092 Stage II 171 1.968 (1.426-2.715) -0.001 0.336 (0.112-1.179) 0.092 Stage II 171 1.968 (1.426-2.715) -0.001 0.337 (0.112-1.179) 0.092 Stage II 172 0.41 Reference 0.001 1.976 (0.812-4.902) 0.613 T3 91 1.325 (0.859-2.044) 0.203 1.197 (0.812-4.902) 0.633 Na ape 403 1.604 (1.183-2.258) 0.001 5.829 (2.132-15.03) 0.006 N2 249 0.5279 (0.984-7.014) 0.083	Characteristics	Total (N)	Univariate analysis		Multivariate analysis	
Galar 47 Fanale: 172 Reference Male 285 L037 (0.821-1309) 0.763 Pathologis stage: 14 14 14 Stage I 77 Reference 12 Stage II 130 1.368 (1.0380-194) 0.055 0.411 (0.139-0.877) 0.021 Stage II 140 1.968 (1.426-271) 0.001 0.379 (0.115-1.25) 0.112 Stage II 140 Reference 12 1.96 (0.598-2300) 0.613 Tage 32 1.2129 (1.387-3268) 0.902 1.196 (0.598-2300) 0.613 Tage 13 2.129 (1.387-3268) 0.902 1.96 (0.588-704) 0.633 Nate 14 1.520 (1.387-3268) 0.903 2.496 (0.888-704) 0.633 Nate 14 1.520 (1.387-3268) 0.903 2.597 (0.904-7353) 0.601 Nate 14 1.542 (1.482-258) 0.903 2.597 (0.904-7353) 0.601 Nate 14 1.626 (1.552-329) 0.904			Hazard ratio (95% CI)	<i>p</i> -value	Hazard ratio (95% CI)	<i>p</i> -value
Pende172ReferenceMale283ConstantiantsSange I74ReferenceSange II174A348 (0.380-1.344)0.0650.411 (0.39-0.877)0.021Sange II174A348 (0.380-3.244)0.0050.027 (0.151-2.54)0.021Sange II174A348 (0.380-3.244)0.0010.279 (0.151-2.54)0.021Taray1821100.029 (0.151-2.54)0.021Taray1821100.029 (0.151-2.54)0.021Taray1831100.029 (0.151-2.54)0.021Taray1831100.029 (0.151-2.54)0.021Taray1831100.029 (0.151-2.54)0.021Taray1831100.0210.021 (0.170-0.287)0.021Taray1831100.021110 (0.059-2.390)0.021Naray193Caference1100.0210.0210.021Naray194Caference110110Maray193Caference110110Maray194Caference110110Naray194Caference110110Naray194Caference110110Naray194Caference110110Naray194Caference110110Naray194 </td <td>Gender</td> <td>457</td> <td></td> <td></td> <td></td> <td></td>	Gender	457				
Mair2851.037 (0.821-1.309)0.763Pathogic stage:141Stage I176ReferenceStage II1701.968 (1.426-2.715)-0.0010.0363 (0.112-1.179)0.021Stage IV233.438 (1.938-542)-0.0010.0363 (0.112-1.179)0.021Stage IV233.438 (1.938-542)-0.0010.0370 (0.112-1.54)0.012Tatge62T141ReferenceT2770.995 (0.639-1.548)0.9011.975 (0.812-4.802)0.631T30.911.325 (0.892-0.94)0.2031.847 (0.70-4.287)0.703T41530.212 (1.387-3.288)-0.0011.975 (0.812-4.802)0.833Nage40ReferenceNa741.634 (1.183-2.285)0.0032.496 (0.888-7.014)0.803N3520.296 (2.094-1.55)0.0382.579 (0.904-7.353)0.706N4741.634 (1.83-2.285)0.0032.496 (0.888-7.014)0.801Na741.634 (1.83-2.536)0.0032.496 (0.888-7.014)0.801Na631.946 (0.862-1.50)0.0382.579 (0.904-7.53)0.706Na164ReferenceMade1741.564 (0.852-1.50)0.016Na1631.946 (0.862-1.50)0.7011.434 (0.852-2.12)0.802Na164Reference-<	Female	172	Reference			
Pathologic steps41Sige I77ReferenceSige II1401.36 (0.801-44)0.0650.411 (0.93 0.87)0.001Sige II1601.36 (0.426.27)50.0010.37 (0.112-129)0.012Sige IV230.384 (1.989-5402)0.0010.379 (0.115-124)0.012Tage730.995 (0.591-548)0.9021.196 (0.598-2590)0.613Tage730.995 (0.591-548)0.9021.970 (0.598-2590)0.613Tage740.995 (0.591-548)0.9021.970 (0.02-527)0.703Tage740.295 (0.592-0.40)0.0101.970 (0.02-528)0.013Tage740.502 (0.02-2.02)0.0032.950 (0.98-7.04)0.010Name740.502 (0.02-2.02)0.0032.950 (0.98-7.04)0.001Name740.502 (0.02-2.02)0.0032.970 (0.947.353)0.001Name740.502 (0.22-5.20)0.0042.970 (0.947.353)0.001Name740.202 (0.25-5.20)0.0015.82 (1.21-5.03)0.001Mare740.202 (0.25-5.20)0.0015.82 (1.21-5.03)0.001Mare740.202 (0.25-5.20)0.0015.82 (1.21-5.03)0.001Mare740.202 (0.25-5.20)0.0141.42 (0.92-2.12)0.01Mare741.62 (0.22-5.12)0.0111.43 (0.92-2.12)0.01Mare741.62 (0.22-5.12)0.0141.201 (0.04-5.78)0.02Mare <t< td=""><td>Male</td><td>285</td><td>1.037 (0.821-1.309)</td><td>0.763</td><td></td><td></td></t<>	Male	285	1.037 (0.821-1.309)	0.763		
Skage I 77 Reference Skage II 140 1.381 (0.980-11,94) 0.065 0.411 (0.19.5 0.877) 0.021 Skage II 17 1.968 (1.426-27.15 0.001 0.370 (0.112-1.129) 0.020 Stage II 0.23 0.438 (1.982-95.20) 0.001 0.370 (0.112-1.129) 0.021 T stage 0.23 0.985 (0.689-1.648) 0.982 1.196 (0.982-380) 0.613 T A 1.41 Reference 0.011 1.975 (0.812-4.802) 0.013 T A 1.63 0.202 (0.323-205) 0.003 2.496 (0.888-7.014) 0.803 N A 0.74 1.634 (1.183-2.28) 0.003 2.496 (0.888-7.014) 0.803 N A 0.74 1.634 (1.183-2.28) 0.003 2.496 (0.888-7.014) 0.801 N A 0.74 1.632 (1.023-2.020) 0.038 2.579 (0.904-7.533) 0.706 N A 4.94 2.020 (1.253-3.290) 0.001 2.82 (1.21-5.933) 0.701 N A 1.94 1.945 (1.228 - 1.21) 0.001 1.413 (0.8	Pathologic stage	411				
shqe II1401.381 (0.380-1.94)0.0650.411 (0.193-0.877)0.021Shqe IV233.438 (1098-5.942)0.0010.363 (0.112-1.79)0.021Shqe IV363.438 (1098-5.942)0.0010.379 (0.115-1.24)0.102Tage370.995 (0.839-5.948)0.9221.196 (0.598-2.390)0.613TJ41Reference1.197 (0.704-4.27)0.131T41330.219 (1.387-3.268)0.0011.975 (0.812-4.802)0.133Nage43Keference1.197 (0.994-7.353)0.601N1741.634 (1.183-2.28)0.0032.496 (0.888-7.014)0.801N21.632 (1.023-2.05)0.0382.579 (0.904-7.353)0.601N21.632 (1.023-2.05)0.0382.579 (0.904-7.353)0.601Mage432.026 (1.255-3.269)0.0362.599 (1.32-1.533)0.601Mage362.026 (1.255-3.269)0.0041.911.91Mage362.026 (1.255-3.269)0.0041.911.91Mage361.364 (0.862-2.150)0.1011.911.91Mage371.720 (0.496 - 2.78)0.6201.921.92Mage1371.223 (0.513 - 2.15)0.6011.433 (0.92-2.12)0.62Mage1361.224 (1.232 - 1.12)0.6011.433 (0.92-2.12)0.62Mage1371.926 (1.228 - 1.12)0.6141.624 (1.228 - 1.12)0.614Mage1381.626 (1.228 - 1.12)0.614<	Stage I	77	Reference			
Singe III1711.968 (1.426-2715)<0.0010.0363 (0.112-1.79)0.092Singe IV2336.010.079 (0.115-1.254)0.112T areg32 </td <td>Stage II</td> <td>140</td> <td>1.381 (0.980-1.944)</td> <td>0.065</td> <td>0.411 (0.193-0.877)</td> <td>0.021</td>	Stage II	140	1.381 (0.980-1.944)	0.065	0.411 (0.193-0.877)	0.021
İsage IV233.438 (1.989-5.942) .0.001 0.737 (0.115-1.254)0.112T stage63T 141ReferenceT 2770.995 (0.639-1.548)0.9221.196 (0.598-2.390)0.613T 31.320.837 2.689 2.044)0.2031.817 (0.770-4.287)0.173T 41.530.203 (0.837-2.88)-0.0011.975 (0.812-4.802)0.013N stage024Reference0.0032.496 (0.888-7.014)0.023N 1741.634 (1.183-2.286)0.0032.496 (0.888-7.014)0.023N 20.920.0382.579 (0.904-7.335)0.076N 3640.0210.0142.579 (0.904-7.335)0.076N 4740.624 (1.282-2.05)0.0382.579 (0.904-7.335)0.076N 4064Centerce111M 40242.022 (1.252-2.02)0.0312.496 (0.888-7.014)0.021M 4024Reference11111M 40242.022 (1.252-2.02)0.0142.121 (1.91.611)0.021M 401671.075 (0.834-1.386)0.57711111M 411621.075 (0.834-1.386)0.5771111111111111111111111111111111111	Stage III	171	1.968 (1.426-2.715)	<0.001	0.363 (0.112-1.179)	0.092
T stage362T41ReferenceT2730.995 (0.639-1.548)0.9231.196 (0.598-2.904)0.613T41530.219 (1.387-3.268)-0.0011.975 (0.812-4.802)0.613T41530.219 (1.387-3.268)-0.0011.975 (0.812-4.802)0.013N stage403N1274ReferenceN12740.620 (1.023-2.05)0.0032.496 (0.888-7.014)0.001N3562.965 (2.096 4.195)-0.0015.829 (2.132-15.933)-0.001M stage431M stage431Marce431Ference193ReferenceMarce193ReferenceMarce193ReferenceNo143ReferenceNo146Reference <td>Stage IV</td> <td>23</td> <td>3.438 (1.989-5.942)</td> <td>< 0.001</td> <td>0.379 (0.115-1.254)</td> <td>0.112</td>	Stage IV	23	3.438 (1.989-5.942)	< 0.001	0.379 (0.115-1.254)	0.112
I1 41 Referece T2 77 0.959 (0.639-1.54) 0.982 1.166 (0.598-2.30) 0.013 T3 9.1 1.252 (0.859-2.04) 0.020 1.817 (0.704-2.87) 0.13 T4 153 0.201 (0.323-2.08) 0.001 1.817 (0.704-2.87) 0.13 N stage 0.33 1.817 (0.704-2.87) 0.013 1.817 (0.704-2.87) 0.013 N stage 0.33 2.496 (0.888-7.014) 0.83	T stage	362				
T2 77 0.995 (0.639-1.548) 0.982 1.196 (0.598-2.59) 0.613 T3 91 1.32 (0.859-2.044) 0.203 1.817 (0.770-4.27) 0.173 T4 13 0.219 (1387.3268) 4.001 1.975 (0.812-4.802) 0.013 Natage 024 Reference 1 0.003 2.496 (0.888-7.014) 0.003 NA 74 1.634 (1.83-2.258) 0.003 2.496 (0.887-0.14) 0.003 NA 74 1.634 (1.83-2.258) 0.003 2.496 (0.887-0.14) 0.003 NA 74 1.634 (1.83-2.258) 0.003 2.496 (0.887-0.14) 0.003 NA 75 0.502 (1.22-2.05) 0.004 5.89 (2.132-15.93) 0.004 Mage 43 2.026 (1.255-3.69) 0.004 5.89 (2.132-15.93) 0.004 Tumbise site 13 1.075 (0.834-1.38) 0.577 1.196 (0.496-2.159) 0.101 1.414 (0.982-2.121) 0.021 Meanoma ulceration 13 1.196 (0.864-2.159) 0.130 1.423 (0.492-3.121) 0.021 Mathematic Relevance 14 1.095 (0.844-1.63) 0.372	T1	41	Reference			
T3 91 1.325 (0.859-2.044) 0.203 1.817 (0.770-4.287) 0.13 T4 153 2.129 (1.387-3.268) 0.001 1.975 (0.812-4.802) 0.133 N stage 0.00 2.49 Reference 100 0.001 0.975 (0.812-4.802) 0.003 2.496 (0.888-7.014) 0.001 N1 74 1.634 (1.183-2.258) 0.003 2.496 (0.888-7.014) 0.001 N2 49 1.502 (1.023-2.005) 0.003 2.599 (0.904-7.353) 0.001 M3 56 2.965 (2.096-4.195) -0.001 5.829 (2.132-15.93) -0.001 Mage 43 - <	T2	77	0.995 (0.639-1.548)	0.982	1.196 (0.598-2.390)	0.613
T4 153 2.129 (1.387.3.28) <0.001	T3	91	1.325 (0.859-2.044)	0.203	1.817 (0.770-4.287)	0.173
N sige:403N0224RéferenceN1741.634 (1.185-2.28)0.0032.496 (0.887-7.01)0.003N23632.579 (0.904-7.353)0.7010.701N33690.205 (2.096-4.195)0.0015.292 (1.32-1.593)0.701M sige:4312.205 (2.096-4.195)0.004	T4	153	2.129 (1.387-3.268)	< 0.001	1.975 (0.812-4.802)	0.133
N0 24 Reference N1 74 1.634 (1.183-2.258) 0.003 2.496 (0.888-7.014) 0.083 N2 49 1.502 (1.023-2.05) 0.038 2.579 (0.904-7.353) 0.076 N3 56 2.965 (2.906-4.195) <0.01	N stage	403				
N1 74 1.634 (1.183-2258) 0.003 2.496 (0.888-7.014) 0.003 N2 49 1.502 (1.023-2.05) 0.038 2.579 (0.904-7.353) 0.001 M3 56 2.965 (2.096-4.15) <0.001	N0	224	Reference			
N2 49 1.502 (1.023-2.205) 0.038 2.579 (0.904-7.353) 0.001 N3 56 2.965 (2.096-4.195) 0.001 5.829 (2.132-15.933) 0.001 M tage 431	N1	74	1.634 (1.183-2.258)	0.003	2.496 (0.888-7.014)	0.083
N3 56 2.965 (2.096-4.195) <0.001	N2	49	1.502 (1.023-2.205)	0.038	2.579 (0.904-7.353)	0.076
M sage A31 M 0 A97 Reference M A9 A026 (1.255-3.269) 0.004 Tumor tissue site A33 A04 A05 Extentities A90 Reference A05 A04 Mad and neck A96 A154 (0.866-2.150) 0.103 A154 Mead and neck A96 Reference A164 Reference A164 A166 (0.282-2.152) <001 1.443 (0.982-2.121) 0.002 Mo A16 Reference A174 A163 A166 A164	N3	56	2.965 (2.096-4.195) <0.001		5.829 (2.132-15.933)	< 0.001
M0 407 Referece M1 24 2.026 (1.255-3.269) 0.004 Tumor tissue site 393	M stage	431				
M1 24 2.026 (1.255.3.269) 0.004 Turot tissue site 393 Externities 190 Reference Trunk 167 1.075 (0.834.1.386) 0.577 Head and neck 36 1.054 (0.866-2.150) 0.180 Melanoma ulceration 313	M0	407	Reference			
\Box runs39kerenities109ReferenceTrunk1671.075 (0.834.1.386)0.577Head and neck361.364 (0.866.2.150)0.180 \Box land neck313	M1	24	2.026 (1.255-3.269)	0.004		
Extremities 190 Reference Trunk 167 1.075 (0.834.1.38) 0.577 Head and neck 36 1.364 (0.866.2.150) 0.180 Melanoma ulceration 313	Tumor tissue site	393				
Trank 167 1.075 (0.834.1.386) 0.577 Head and neck 36 1.364 (0.866.2.150) 0.180 Melanoma duceration 313	Extremities	190	Reference			
Head and neck 36 1.364 (0.866-2.150) 0.180 Melanoma ulceration 313	Trunk	167	1.075 (0.834-1.386)	0.577		
MeLanoma ulceration313No164ReferenceYes1671.626 (1.228 - 2.152)<0.001	Head and neck	36	1.364 (0.866-2.150)	0.180		
No 146 Reference Yes 167 1.626 (1.228-2.152) <0.001	Melanoma ulceration	313				
Yes 167 1.626 (1.228-2.152) <0.001 1.443 (0.982-2.121) 0.062 Melanoma clark level 315 . <td>No</td> <td>146</td> <td>Reference</td> <td></td> <td></td> <td></td>	No	146	Reference			
Melanoma dark level 315 I and II 19 Reference III 76 1.333 (0.709-2.505) 0.372 1.170 (0.496-2.758) 0.720 IV 167 1.908 (1.048-3.473) 0.034 1.223 (0.513-2.915) 0.650 V 53 4.821 (2.486-9.349) <001	Yes	167	1.626 (1.228-2.152) < 0.001		1.443 (0.982-2.121)	0.062
I and II 19 Reference III 76 1.333 (0.709-2.505) 0.372 1.170 (0.496-2.758) 0.720 IV 167 1.908 (1.048-3.473) 0.034 1.223 (0.513-2.915) 0.650 V 53 4.821 (2.486-9.349) <0.001	Melanoma clark level	315				
III761.333 (0.709-2.505)0.3721.170 (0.496-2.758)0.720IV1671.908 (1.048-3.473)0.0341.223 (0.513-2.915)0.650V534.821 (2.486-9.349)<0.001	I and II	19	Reference			
IV 167 1.908 (1.048-3.473) 0.034 1.223 (0.513-2.915) 0.650 V 53 4.821 (2.486-9.349) <0.001 3.211 (1.193-8.645) 0.021 Age 457 0.021 S60 247 Reference <td>III</td> <td>76</td> <td>1.333 (0.709-2.505)</td> <td>0.372</td> <td>1.170 (0.496-2.758)</td> <td>0.720</td>	III	76	1.333 (0.709-2.505)	0.372	1.170 (0.496-2.758)	0.720
V 53 4.821 (2.486-9.349) <0.001 3.211 (1.193-8.645) 0.021 Age 457 </td <td>IV</td> <td>167</td> <td colspan="2">1.908 (1.048-3.473) 0.034</td> <td>1.223 (0.513-2.915)</td> <td>0.650</td>	IV	167	1.908 (1.048-3.473) 0.034		1.223 (0.513-2.915)	0.650
Age 457 ≤60 247 Reference >60 210 1.576 (1.240-2.002) <0.001	V	53	4.821 (2.486-9.349)	< 0.001	3.211 (1.193-8.645)	0.021
≤60 247 Reference >60 210 1.576 (1.240-2.002) <0.001	Age	457				
>60 210 1.576 (1.240-2.002) <0.001 1.395 (0.988-1.970) 0.059 TIMM13 457	≤60	247	Reference			
TIMM13 457 Low 230 Reference High 227 1.303 (1.041-1.631) 0.021 1.439 (1.041-1.990) 0.027	>60	210	1.576 (1.240-2.002)	<0.001	1.395 (0.988-1.970)	0.059
Low 230 Reference High 227 1.303 (1.041-1.631) 0.021 1.439 (1.041-1.990) 0.027	TIMM13	457				
High 227 1.303 (1.041-1.631) 0.021 1.439 (1.041-1.990) 0.027	Low	230	Reference			
	High	227	1.303 (1.041-1.631)	0.021	1.439 (1.041-1.990)	0.027

TABLE 3 Univariate and multivariate Cox regression analysis of PFI.

Bold values represent significantly different.

Similar results were obtained by detecting CD8 + T lymphocyte infiltration using the TIMER database, suggesting that TIMM13 could play a key role in inhibiting SKCM immune infiltration and was related to tumor microenvironment.

The correlation between TIMM13 and different TILs' biomarkers in SKCM was studied by using the Xiantao tool. We found that TIMM13 was associated with most TILs' markers in SKCM. Several functional T lymphocytes,



including Th1, Tregs and exhausted T lymphocytes, were also investigated. In particular, TIMM13 is significantly associated with most sets of TILs immunomarkers in SKCM (Table 4).

Furthermore, TIMM13 was significantly associated with most of monocytes, TAM, M2 macrophages and T cell exhaustion markers in SKCM (**Table 4**). As shown in the table, PD-1, PDL1, CTLA4, LAG3, TIM-3, GZMB of T-cell exhaustion, and CCL-2, CD68, IL10 of TAMs, IRF5 of M1 phenotype and CD163, VSIG4 and MS4A4A of M2 phenotype were almost negatively correlated with TIMM13 in SKCM (p < 0.0001). It was suggested that TIMM13 could regulate exhaustion, and macrophage polarization in SKCM.

The expression of TIMM13 is related to immunoinhibitors and immunostimulators in SKCM

Immunoinhibitors and immunostimulators are substances that influence the function of the immune system. This study showed that TIMM13 was significantly associated with immunoinhibitors (p < 0.001), such as BTLA (rho = -0.389), CD274 (rho = -0.476), CD96 (rho = -0.404), IL10 (rho = -0.328), PDCD1LG2 (rho = -0.458), and TIGIT (rho = -0.342) (Figure 5A). The expression of TIMM13 was also significantly associated with immunostimulators (p < 0.001), including CD28 (rho = -0.389), CD80 (rho = -0.44), IL2RA (rho = -0.434), TNFRSF9 (rho = -0.417), TNFSF13B (rho = -0.402), TNFSF4 (rho = -0.396) (Figure 5B). These results proposed that TIMM13 was intimately engaged in the regulation of the immune interaction and might modulate tumor immune escape.

Correlation between the TIMM13 expression and chemokines/receptors in SKCM

Chemokines played a great function in controlling the infiltration degree of immune cell. This research implicated a significant association between TIMM13 expression and chemokines. For instance, the expression of TIMM13 was significantly associated with CCL8 (rho = -0.293), CXCL9 (rho = -0.359), CXCL10 (rho = -0.347), CXCL10 (rho = -0.347), CXCL11 (rho = -0.375), CXCL12 (rho = -0.33), and CXCL13 (rho = -0.372) (**Figure 6A**). All the values of *p* were < 0.001. At the same time, we found that the expression of TIMM13 was also significantly related with chemokine receptors (*p* < 0.001), including CCR1 (rho = -0.375), CCR2 (rho = -0.362), CCR8 (rho = -0.432), XCR1 (rho = -0.385) (**Figure 6B**). These results further suggested that TIMM13 may be an immunoregulatory factor in SKCM.

Construction and validation of a nomogram

A nomogram was built for the training set based on the gender, pathologic stage, TNM stage, age, and TIMM13 expression (Figure 7A). The C-index of the nomogram was 0.715(0.693–0.736). The calibration plots for the 1-, 3-, and 5-year survivals indicated good agreement between the actual observations and the predictions (Figure 7B). These results indicated that the prediction performance of the nomogram was good.



in SKCM available at Xiantao tool. Correlation of ITGAL expression with infiltration levels of Th1 cells (C), T cells (D), aDC (E), TFH (F), B cells (G), and T helper in SKCM (H). (I) Correlation between the expression of TIMM13 and the abundance of TILs in SKCM validation at TIMER database.

Description	Gene markers	Cor	p	
CD8 ⁺ T cell	CD8A	-0.373	< 0.001	
	CD8B	-0.353	< 0.001	
T cell (general)	CD3D	-0.358	< 0.001	
CD8* T cellCD8A CD8BT cell (general)CD3D CD3E CD2B cellCD19 CD79AMonocyteCD86 CD115 (CSF1R)TAMCCL2 CD68 IL10M1 MacrophageIRF5M2 MacrophageCD163 VSIG4 MS4A4ANeutrophilsCD11b (ITGAM) CCR7Natural killer cellKIR2DL1 KIR3DL1 KIR3DL2 KIR2DS4Dendritic cellHLA-DPB1 HLA-DPA1 BDCA-1(CD1C) BDCA-4(NRP1) CD11c (ITGAX)Th1T -bet (TBX21) STAT4 STAT1 IFN-v (IENG)	-0.353	< 0.001		
	CD2	-0.370	< 0.001	
B cell	CD19	-0.315	< 0.001	
	CD79A	-0.323	< 0.001	
Monocyte	CD86	-0.368	< 0.001	
,	CD115 (CSF1R)	-0.287	< 0.001	
ТАМ	CCL2	-0.200	< 0.001	
	CD68	-0.165	< 0.001	
	IL10	-0.240	< 0.001	
M1 Macrophage	IRF5	-0.304	< 0.001	
M2 Macrophage	CD163	-0.285	<0.001	
ing maerophage	VSIG4	-0.248	< 0.001	
	MS4A4A	-0.322	< 0.001	
Neutrophils	CD11b (ITGAM)	-0.286	< 0.001	
I	CCR7	-0.303	< 0.001	
Natural killer cell	KIR2DL1	-0.131	0.004	
	KIR3DL1	-0.154	< 0.001	
	KIR3DL2	-0.271	< 0.001	
	KIR2DS4	-0.133	0.004	
Dendritic cell	HLA-DPB1	-0.301	< 0.001	
	HLA-DQB1	-0.287	< 0.001	
	HLA-DRA	-0.345	< 0.001	
	HLA-DPA1	-0.330	< 0.001	
	BDCA-1(CD1C)	-0.255	< 0.001	
	BDCA-4(NRP1)	-0.156	< 0.001	
	CD11c (ITGAX)	-0.2271	< 0.001	
Th1	T -bet (TBX21)	-0.337	< 0.001	
	STAT4	-0.372	< 0.001	
	STAT1	-0.308	< 0.001	
	$TNF-\alpha$ (TNF)	-0.365	< 0.001	
TLO		0.202	<0.001	
1112	STAT5A	-0.280	< 0.001	
Tfb	BCI6	-0.267	<0.001	
1 111	IL21	-0.384	< 0.001	
Th17	STAT3	-0.201	<0.001	
	SIAIS	-0.201	<0.001	
Treg	FOXP3	-0.249	< 0.001	
	STAT5B	-0.3/1 -0.217	< 0.001	
T		0.217	0.001	
1 cell exhaustion	PD-1 (PDCD1)	-0.288	< 0.001	
	CTI 44	-0.3/1	<0.001	
	LAG3	-0.260	< 0.001	
	TIM-3 (HAVCR2)	-0.345	< 0.001	
	GZMB	-0.270	< 0.001	

TABLE 4 Correlation analysis between ITGAL and related genes and markers of immune cells in Xiantao tool.

Histologic analysis

We next explored the protein expression levels of TIMM13 between melanoma and normal skin tissues. The IHC staining results showed that TIMM13 showed higher expression levels in melanoma tissues (n = 25) than in normal skin tissues

(n = 15) (Figures 8A,B). The patients' characteristics were shown in Table 5.

Discussion

In this study, the expression level of TIMM13 in SKCM and its clinical significance were comprehensively studied by bioinformatics. Our results showed that poor prognosis was in accordance with high expression of TIMM13 in SKCM. The expression of TIMM13 is closely related to the infiltration of various immune cells, immunomodulators, chemokines and receptors in SKCM. Therefore, our study provided new insights into the key functions of TIMM13, which might be a prognostic biomarker related to immune infiltration of SKCM.

TIMM13 partners with TIMM8a in the mitochondrial intermembrane space to form a 70 kDa complex and facilitates the import of the inner membrane substrate TIMM23 (9). Kim SH et al. reported that TIMM13 functions as a target gene of miRNA-1273g-3p to contribute to Alzheimer's Disease pathogenesis by regulating expression of mitochondrial genes (22). Roesch K et al. reported that human deafness dystonia syndrome was caused by a defect in assembly of the DDP1/TIMM8a-TIMM13 complex. Timm13 is related to Mohr-Tranebjaerg Syndrome and Visual Cortex Disease. Among its related pathways are Peroxisomal lipid metabolism. Several studies have shown that TIMM13 was differently expressed in metastatic susceptibility (13), hepatocellular carcinoma (14), breast cancer (15) et al. These researchers suggested that TIMM13 might have a significant influence on cancer, and may be a novel target in treating a variety of malignancies. However, the possible function of TIMM13 in regulating tumor immunity and its clinical significance in SKCM are still unknown.

Therefore, we computed the TIMM13 expression for SKCM using the Xiantao tool and the UALCAN database. We found that TIMM13 was abnormally expressed in the tissues of various malignant tumors. TIMM13 in SKCM was significantly higher than that in adjacent tissues. Using the HPA database, we also found that TIMM13mRNA and protein levels in most SKCM samples were higher than those in matched paracancer samples. It was suggested that the expression level of TIMM13 could be used as a diagnostic indicator of SKCM with the AUC is 0.757. In addition, in order to determine whether TIMM13 could be used as a biomarker for prognosis, we analyzed the correlation between TIMM13 expression and OS, and FPI in SKCM patients with the Xiantao tool. Furthermore, to confirm whether TIMM13 can be used as a prognostic biomarker, we used the xiantao tool to analyze the correlation between the TIMM13 expression and OS, DSS, and FPI in SKCM patients. Notably, analysis of this database indicated that the higher TIMM13 expression correlated with HR for worse OS DSS, and poorer



FIGURE 5

The expression of TIMM13 is associated with immunomodulators in SKCM. (A) Correlation between TIMM13 expression and immunoinhibitors in SKCM available at TISIDB database. (B) Correlation between TIMM13 expression and immunostimulators in SKCM available at TISIDB database. Color images are available online.



FIGURE 6

Correlation between the expression of TIMM13 and chemokines in SKCM. (A) Correlation between TIMM13 expression and chemokines in SKCM available at TISIDB database. (B) Correlation between TIMM13 expression and chemokine receptors in SKCM available at TISIDB database. Color images are available online.





PPS of SKCM. In addition, upregulated TIMM13 expression had a significant correlation with a worse prognosis of SKCM in T4 stage, N1 stage, N2 stage, N3 stage. Taken together, these observations supported our hypothesis that TIMM13 was a prognostic biomarker in SKCM.

Additionally, this study found that TIMM13 was correlated with the degree of immune infiltration of SKCM. In the cancer microenvironment, immune cell infiltration had been proved to play a key role in the development and progression of cancer (23, 24). TIMM13 is a chaperone protein, which plays a key role in transporting cytoplasmic proteins into the mitochondrial inner membrane. At present, it is not clear whether the expression of TIMM13 is related to the immune infiltration of SKCM. Therefore, we systematically discussed the relationship between TIMM13 expression and immune infiltration degree of SKCM. Based on our results, it was found for the first time that TIMM13 modulates immune infiltration through SKCM.

The expression of TIMM13 was closely related to the expression of TILs in CD8 + T cells, CD4 + T cells, Treg cells, and TAM cells. Meanwhile, the increase of TIMM13 expression was related to immunoregulators, chemokines and

TABLE 5 Clinical characteristics of melanoma patients.

ID	Sex	Age,y	Location	Primary/metastasis
Case1	М	54	Right plantar	Primary
Case2	F	35	Left plantar	Primary
Case3	М	82	Left plantar	Primary
Case4	F	39	Right ankle	Primary
Case5	М	62	Left plantar	Metastasis
Case6	М	44	Left plantar	Metastasis
Case7	М	55	Right plantar	Metastasis
Case8	F	57	Right plantar	Metastasis
Case9	F	48	Face	Primary
Case10	М	73	Left plantar	Primary
Case11	М	64	Left plantar	Metastasis
Case12	М	65	Right plantar	Primary
Case13	М	66	Right plantar	Metastasis
Case14	F	58	Right plantar	Primary
Case15	F	64	Right plantar	Primary
Case16	F	74	Right arm	Primary
Case17	М	66	Right plantar	Metastasis
Case18	М	57	Right plantar	Primary
Case19	М	52	Back	Primary
Case20	М	63	Left plantar	Metastasis
Case21	F	74	Right plantar	Metastasis
Case22	F	71	Left ankle	Primary
Case23	М	63	Left plantar	Primary
Case24	М	41	Left arm	Metastasis
Case25	М	52	Head	Metastasis

F, female; M, male.

receptors. Additionally, the study proposed the relationship between TIMM13 expression and TILs' marker genes of SKCM. The expression of TIMM13 was associated with M2 macrophage markers CD163, VSIG4, and MS4A4A, while M1 macrophage markers NOS2 and IRF5 were slightly associated with the expression of TIMM13. Macrophages played an important role in tumor proliferation (25), angiogenesis (26), invasion (27), metastasis (27) and tumor immunity (28). These results demonstrated that TIMM13 had the potential function of regulating TAMs polarization. The up-regulation of TIMM13 was closely related to Tregs markers (FOXP3, CCR8) and T lymphocyte depletion markers (PD1, CTLA4, LAG3). Blocking immune checkpoints is the main strategy of immunotherapy (29). The most important thing is to enhance the response of tumor cells to immune checkpoint inhibitors and cytokines (30, 31). According to TISIDB, TIMER and Xiantao tool, our results showed that the up-regulation of TIMM13 expression was not only related to PD1 and CTLA4, but also significantly related to cell response to chemokines. These results suggested that targeting TIMM13 may be a strategy to improve the efficacy of immunotherapy. It was also

suggested that TIMM13 played an important role in the recruitment and regulation of TILs in SKCM, and its molecular mechanism and role in the regulation of tumor microenvironment deserve further study.

However, there are also some limitations in our research. One limitation is that most of the data is based on online platforms, which are constantly updated and extended; So, the research results may be influenced. Secondly, our study did not include any information about complications and therapy options. Thirdly, *in vivo* and *in vitro* experiments are not to verify the role of TIMM13 in SKCM. However, in future research, we are committed to paying more attention to the background information of patients and conducting experiments to further verify the expected results.

Conclusions

The increased expression of TIMM13 was closely related to poor prognosis of SKCM and increased immune infiltration of CD8 + T lymphocytes, C4 + T lymphocytes, and myeloid dendritic cells. The expression of TIMM13 might be involved in the regulation of M2, Treg, and T -cell exhaustion. So, this study suggested that TIMM13 might have a new potential function in the regulation of immune cell infiltration in SKCM patients.

Data availability statement

The original contributions presented in the study are included in the article/Suplementary Material, further inquiries can be directed to the corresponding author/s.

Author contributions

RHY, XBP, and JHL designed the study. STZ and YYH conducted most of the experiments, data analysis, and wrote the manuscript. RHY, XBP, and JHL had full access to all of the data in the manuscript and takes responsibility for the integrity of the data and the accuracy of the data analysis. All authors contributed to the article and approved the submitted version.

Funding

This study was supported by the National Natural Science Foundation of China (82002913), Guangdong Basic and Applied Basic Research Foundation (2021A1515011453, 2022A1515012160, 2021B1515120036, and 2022A1515012245), the Medical Scientific Research Foundation of Guangdong Province (A2022293), Foshan 14th - fifth high-level key specialty construction project, Yunnan Fundamental Research Projects (grant NO. 202001AT070145, 202101AT070288).

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

References

1. Elder DE, Bastian BC, Cree IA, Massi D, Scolyer RA. The 2018 world health organization classification of cutaneous, mucosal, and uveal melanoma: detailed analysis of 9 distinct subtypes defined by their evolutionary pathway. *Arch Pathol Lab Med.* (2020) 144(4):500–22. doi: 10.5858/arpa.2019-0561-RA

2. Timar J, Ladanyi A. Molecular pathology of skin melanoma: epidemiology, differential diagnostics, prognosis and therapy prediction. *Int J Mol Sci.* (2022) 23(10):5384. doi: 10.3390/ijms23105384

3. Villani A, Potestio L, Fabbrocini G, Troncone G, Malapelle U, Scalvenzi M. The treatment of advanced melanoma: therapeutic update. *Int J Mol Sci.* (2022) 23(12):6388. doi: 10.3390/ijms23126388

4. Rebecca VW, Somasundaram R, Herlyn M. Pre-clinical modeling of cutaneous melanoma. *Nat Commun.* (2020) 11(1):2858. doi: 10.1038/s41467-020-15546-9

5. Schadendorf D, van Akkooi ACJ, Berking C, Griewank KG, Gutzmer R, Hauschild A, et al. Melanoma. *Lancet.* (2018) 392(10151):971-84. doi: 10.1016/S0140-6736(18)31559-9

6. Kim G, McKee AE, Ning YM, Hazarika M, Theoret M, Johnson JR, et al. FDA Approval summary: vemurafenib for treatment of unresectable or metastatic melanoma with the BRAFV600E mutation. *Clin Cancer Res.* (2014) 20 (19):4994–5000. doi: 10.1158/1078-0432.CCR-14-0776

7. Rajkumar S, Berry D, Heney KA, Strong C, Ramsay L, Lajoie M, et al. Melanomas with concurrent BRAF non-p.V600 and NF1 loss-of-function mutations are targetable by BRAF/MEK inhibitor combination therapy. *Cell Rep.* (2022) 39(1):110634. doi: 10.1016/j.celrep.2022.110634

8. Kuryk L, Bertinato L, Staniszewska M, Pancer K, Wieczorek M, Salmaso S, et al. From conventional therapies to immunotherapy: melanoma treatment in review. *Cancers (Basel)*. (2020) 12(10):3057. doi: 10.3390/cancers12103057

9. Roesch K, Hynds PJ, Varga R, Tranebjaerg L, Koehler CM. The calciumbinding aspartate/glutamate carriers, citrin and aralar1, are new substrates for the DDP1/TIMM8a-TIMM13 complex. *Hum Mol Genet.* (2004) 13 (18):2101–11. doi: 10.1093/hmg/ddh217

10. Roesch K, Curran SP, Tranebjaerg L, Koehler CM. Human deafness dystonia syndrome is caused by a defect in assembly of the DDP1/TIMM8a-TIMM13 complex. *Hum Mol Genet.* (2002) 11(5):477–86. doi: 10.1093/hmg/11. 5.477

11. Blesa JR, Solano A, Briones P, Prieto-Ruiz JA, Hernandez-Yago J, Coria F. Molecular genetics of a patient with Mohr-Tranebjaerg Syndrome due to a new mutation in the DDP1 gene. *Neuromolecular Med.* (2007) 9(4):285–91. doi: 10. 1007/s12017-007-8000-3

12. Shi X, Huang Z, Zhou G, Li C. Dietary protein from different sources exerted a great impact on lipid metabolism and mitochondrial oxidative phosphorylation in rat liver. *Front Nutr.* (2021) 8:719144. doi: 10.3389/fnut.2021.719144

13. Hu Y, Wu G, Rusch M, Lukes L, Buetow KH, Zhang J, et al. Integrated crossspecies transcriptional network analysis of metastatic susceptibility. *Proc Natl Acad Sci U S A*. (2012) 109(8):3184–9. doi: 10.1073/pnas.1117872109

14. Li Z, Song G, Guo D, Zhou Z, Qiu C, Xiao C, et al. Identification of GINS2 prognostic potential and involvement in immune cell infiltration in hepatocellular carcinoma. *J Cancer.* (2022) 13(2):610–22. doi: 10.7150/jca.53841

15. Sanchez-Alvarez R, De Francesco EM, Fiorillo M, Sotgia F, Lisanti MP. Mitochondrial fission factor (MFF) inhibits mitochondrial metabolism and reduces breast cancer stem cell (CSC) activity. *Front Oncol.* (2020) 10:1776. doi: 10.3389/fonc.2020.01776

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

16. Yan Y, Li J, Ye M, Li Z, Li S. Tropomyosin is potential markers for the diagnosis and prognosis of bladder cancer. *Dis Markers*. (2022) 2022:6936262. doi: 10.1155/2022/6936262

17. The Cancer Genome Atlas Network. Genomic classification of cutaneous melanoma. Cell. (2015) 161(7):1681-96. doi: 10.1016/j.cell.2015.05.044

18. Consortium GT. The genotype-tissue expression (GTEx) project. Nat Genet. (2013) 45(6):580–5. doi: 10.1038/ng.2653

19. Chandrashekar DS, Karthikeyan SK, Korla PK, Patel H, Shovon AR, Athar M, et al. UALCAN: an update to the integrated cancer data analysis platform. *Neoplasia.* (2022) 25:18–27. doi: 10.1016/j.neo.2022.01.001

20. Li T, Fu J, Zeng Z, Cohen D, Li J, Chen Q, et al. TIMER2.0 For analysis of tumor-infiltrating immune cells. *Nucleic Acids Res.* (2020) 48(W1):W509-14. doi: 10.1093/nar/gkaa407

21. Ru B, Wong CN, Tong Y, Zhong JY, Zhong SSW, Wu WC, et al. TISIDB: an integrated repository portal for tumor-immune system interactions. *Bioinformatics*. (2019) 35(20):4200–2. doi: 10.1093/bioinformatics/btz210

22. Kim SH, Choi KY, Park Y, McLean C, Park J, Lee JH, et al. Enhanced expression of microRNA-1273g-3p contributes to Alzheimer's disease pathogenesis by regulating the expression of mitochondrial genes. *Cells.* (2021) 10(10):2697. doi: 10.3390/cells10102697

23. Kim S, Kim A, Shin JY, Seo JS. The tumor immune microenvironmental analysis of 2,033 transcriptomes across 7 cancer types. *Sci Rep.* (2020) 10 (1):9536. doi: 10.1038/s41598-020-66449-0

24. Georgescu SR, Tampa M, Mitran CI, Mitran MI, Caruntu C, Caruntu A, et al. Tumour microenvironment in skin carcinogenesis. *Adv Exp Med Biol.* (2020) 1226:123-42. doi: 10.1007/978-3-030-36214-0_10

25. Yan K, Wang Y, Lu Y, Yan Z. Coexpressed genes that promote the infiltration of M2 macrophages in melanoma can evaluate the prognosis and immunotherapy outcome. *J Immunol Res.* (2021) 2021:6664791. doi: 10.1155/2021/6664791

26. Pratt HG, Steinberger KJ, Mihalik NE, Ott S, Whalley T, Szomolay B, et al. Macrophage and neutrophil interactions in the pancreatic tumor microenvironment drive the pathogenesis of pancreatic cancer. *Cancers (Basel)*. (2021) 14(1):194. doi: 10.3390/cancers14010194

27. Zhang H, Luo YB, Wu W, Zhang L, Wang Z, Dai Z, et al. The molecular feature of macrophages in tumor immune microenvironment of glioma patients. *Comput Struct Biotechnol J.* (2021) 19:4603–18. doi: 10.1016/j.csbj.2021.08.019

28. Yin W, Li Y, Song Y, Zhang J, Wu C, Chen Y, et al. CCRL2 Promotes antitumor T-cell immunity via amplifying TLR4-mediated immunostimulatory macrophage activation. *Proc Natl Acad Sci U S A*. (2021) 118(16):e2024171118. doi: 10.1073/pnas.2024171118

29. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. (2012) 12(4):252-64. doi: 10.1038/nrc3239

30. Jenkins L, Jungwirth U, Avgustinova A, Iravani M, Mills AP, Haider S, et al. Cancer-associated fibroblasts suppress CD8+ T cell infiltration and confer resistance to immune checkpoint blockade. *Cancer Res.* (2022). doi: 10.1158/0008-5472. [Epub ahead of print]

31. Asdourian MS, Shah N, Jacoby TV, Semenov YR, Otto T, Thompson LL, et al. Development of multiple cutaneous immune-related adverse events among cancer patients after immune checkpoint blockade. *J Am Acad Dermatol.* (2022). doi: 10.1016/j.jaad.2022.06.030. [Epub ahead of print]